
11/07/2025
$BCTX reports Bria-IMT™ outperformed Trodelvy® in Phase 2 metastatic breast cancer data:
13.9 mo OS in TNBC vs. 11.8 mo (Trodelvy), 6.9 mo (control)
17.3 mo OS in HR+ vs. 14.4 mo (Trodelvy), 11.2 mo (control)
No treatment-related discontinuations
https://www.globenewswire.com/news-release/2025/07/11/3113933/0/en/BriaCell-s-Bria-IMT-Demonstrates-Survival-Advantage-over-Trodelvy-and-Control-Group-in-Metastatic-Breast-Cancer.html